search
Back to results

Evaluation of the "Blue Halo Coil Catheter" for Patients With Prostatic Obstruction (BlueHaloCoil)

Primary Purpose

Urinary Retention

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
blue halo coil catheter
Sponsored by
Blue Halo Biomedical, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urinary Retention

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria: Male subjects > 50 years of age Able to provide consent Participants in urinary retention with post void residual > 350 cc Urinary retention is due to BPH with a prostate volume > 50cc or a prostatic urethral length of 5+ cm Subjects with a PSA > 4 ng/ml and a PSA density of 0.1 or less Subjects on alpha- blocking drugs or 5-alpha-reductase inhibitor drugs may be included Exclusion Criteria Inability to undergo bladder catheterization ( i.e. urethral stricture) Presence of gross hematuria Lack of cognitive ability to give consent or keep appointments History of Prostate Cancer Subject with a PSA > 4 ng/ml and a PSA density of > 0.1 will require prostate biopsy to rule out prostate cancer in order to be considered for study enrollment A subject with a prostate nodule will require biopsy to exclude cancer diagnosis Subject with a PSA > 10 ng/ml Subject taking LHRH analogs or anti-androgen drugs

Sites / Locations

  • Florida Urology PartnersRecruiting
  • Vero Urology CenterRecruiting
  • Urology Clinics of North TexasRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

single arm study

Arm Description

The indication for use of the Blue Halo Coil Catheter is to facilitate bladder drainage in adult male patients with urinary retention due to benign prostatic hyperplasia. The device is inserted for temporary use up to 28 days.

Outcomes

Primary Outcome Measures

The change in Post Void Residual from baseline to day 28 will be measured and reported
The primary effectiveness endpoint of the study is the number of subjects who were able to return to volitional voiding with a post void residual less then 75 cc during a 28-day study period.Post Void Residual will be measured by bladder ultrasound and reported as cc.

Secondary Outcome Measures

Primary safety endpoint
The primary safety endpoint is the number of subjects who had an adverse event related to the Coil Catheter and required removal of the Coil Catheter with an alternative method to drain the bladder, such as an indwelling Foley catheter, or self-intermittent catheterization.
Secondary Safety Endpoint 1
The number of Blue Halo Coil Catheters that were visibly encrusted at the time of removal
Secondary Safety Endpoint 2
The number of participants who experienced urinary obstruction secondary to migration of the Blue Halo Coil Catheter, and required replacement of the device
Secondary Safety Endpoint 3
The number of participants who experienced clinically significant gross hematuria that necessitated removal of the Blue Halo Coil Catheter and placement of a Foley catheter for bladder drainage

Full Information

First Posted
September 20, 2022
Last Updated
January 26, 2023
Sponsor
Blue Halo Biomedical, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05714488
Brief Title
Evaluation of the "Blue Halo Coil Catheter" for Patients With Prostatic Obstruction
Acronym
BlueHaloCoil
Official Title
Study: A Prospective Evaluation of the Blue Halo BioMedical, LLC "Blue Halo Coil Catheter" for Patients With Prostatic Obstruction
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 1, 2022 (Actual)
Primary Completion Date
September 1, 2023 (Anticipated)
Study Completion Date
October 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Blue Halo Biomedical, LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The Investigators will study a device for men in urinary retention secondary to Benign Prostatic Hyperplasia, BPH ,who are catheter dependent or who have a Post Void Residual > 350cc. The hypothesis is that the device will allow these participants to return to volitional voiding with a Post Void Residual <75 cc.
Detailed Description
The indication for use of the Blue Halo Coil Catheter is to facilitate bladder drainage in adult male patients with urinary retention due to benign prostatic hyperplasia. The device is inserted for temporary use up to 28 days. Study participants will have a history of Foley catheter use or self-catheterization to drain their bladder.Participants may include men in urinary retention with no prior intervention. The hypothesis is that the Blue Halo Coil Catheter will reduce the post void residual to <75 cc with volitional voiding. The Blue Halo Coil Catheter is comprised of a Coiled Retention portion with a guidewire accommodating tip, a short prostate catheter segment, and a pusher/delivery catheter segment, that when left in place allows for the temporary collection of urine prior to conversion to short segment without an external collection device. The tip of the Blue Halo Coil Catheter utilizes a horizontal coil retention device. A monofilament suture is attached to the prostate catheter segment to allow for ease of positioning and removal. The suture also allows for repositioning should the device slip back into the bladder.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Retention

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
The Investigators are conducting a single-arm study with one-group posttest only design.Although this study is a non-randomized control trial, the one-arm design avoids selection and treatment diffusion (among other things). The comparator for the coil catheter is inferior and known to cause injury and infection. Therefore, researchers could not ethically randomly assign subjects to a control group that would receive the alternative device for the sake of comparison.
Masking
None (Open Label)
Allocation
N/A
Enrollment
95 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
single arm study
Arm Type
Experimental
Arm Description
The indication for use of the Blue Halo Coil Catheter is to facilitate bladder drainage in adult male patients with urinary retention due to benign prostatic hyperplasia. The device is inserted for temporary use up to 28 days.
Intervention Type
Device
Intervention Name(s)
blue halo coil catheter
Intervention Description
device inserted with coil at the bladder and straight arm in the prostatic urethra proximal to the external sphincter
Primary Outcome Measure Information:
Title
The change in Post Void Residual from baseline to day 28 will be measured and reported
Description
The primary effectiveness endpoint of the study is the number of subjects who were able to return to volitional voiding with a post void residual less then 75 cc during a 28-day study period.Post Void Residual will be measured by bladder ultrasound and reported as cc.
Time Frame
28 days
Secondary Outcome Measure Information:
Title
Primary safety endpoint
Description
The primary safety endpoint is the number of subjects who had an adverse event related to the Coil Catheter and required removal of the Coil Catheter with an alternative method to drain the bladder, such as an indwelling Foley catheter, or self-intermittent catheterization.
Time Frame
28 days
Title
Secondary Safety Endpoint 1
Description
The number of Blue Halo Coil Catheters that were visibly encrusted at the time of removal
Time Frame
28 days
Title
Secondary Safety Endpoint 2
Description
The number of participants who experienced urinary obstruction secondary to migration of the Blue Halo Coil Catheter, and required replacement of the device
Time Frame
28 days
Title
Secondary Safety Endpoint 3
Description
The number of participants who experienced clinically significant gross hematuria that necessitated removal of the Blue Halo Coil Catheter and placement of a Foley catheter for bladder drainage
Time Frame
28 days
Other Pre-specified Outcome Measures:
Title
Bacterial Infection Monitoring
Description
Infection status at the time of insertion and removal of the device will be recorded during the study. Urine culture and sensitivity will be obtained prior to device insertion, at the 28 day removal, and at day 56 follow-up safety visit. The results will be reported as colony forming units, CFU, per ml. Asymptomatic colonization as well as symptomatic Urinary tract infection, UTI, will be reported.
Time Frame
56 days
Title
Trends in Renal Function
Description
Serum Creatinine measured as mg/dl will be measured prior to placement of the Blue Halo Coli Catheter, and repeated at the 28 day device removal and at the day 56 follow-up safety visit. This outcome is to observe if there are any changes in renal function that might be attributable to the device
Time Frame
56 days
Title
Quality of Life Measurement
Description
The SF-8, Short Form- 8 question survey, will be recorded at the screening visit and the 28 day device removal, to observe any change in Quality of Life issues.
Time Frame
28 days
Title
Urinary Bother Inventory
Description
An IRB approved, 4 question, urinary symptom assessment will be recorded at the screening visit, at the 28 day device removal, and at the 56 day safety follow-ip visit.
Time Frame
56 days

10. Eligibility

Sex
Male
Gender Based
Yes
Gender Eligibility Description
biological males with BPH
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male subjects > 50 years of age Able to provide consent Participants in urinary retention with post void residual > 350 cc Urinary retention is due to BPH with a prostate volume > 50cc or a prostatic urethral length of 5+ cm Subjects with a PSA > 4 ng/ml and a PSA density of 0.1 or less Subjects on alpha- blocking drugs or 5-alpha-reductase inhibitor drugs may be included Exclusion Criteria Inability to undergo bladder catheterization ( i.e. urethral stricture) Presence of gross hematuria Lack of cognitive ability to give consent or keep appointments History of Prostate Cancer Subject with a PSA > 4 ng/ml and a PSA density of > 0.1 will require prostate biopsy to rule out prostate cancer in order to be considered for study enrollment A subject with a prostate nodule will require biopsy to exclude cancer diagnosis Subject with a PSA > 10 ng/ml Subject taking LHRH analogs or anti-androgen drugs
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
GAMEEL B HODGE, MD
Phone
407-492-1683
Email
bhodge@bluehalobiomedical.com
First Name & Middle Initial & Last Name or Official Title & Degree
GAINES W HAMMOND, MD
Phone
254-652-2475
Email
gwhoffice@gmail.com
Facility Information:
Facility Name
Florida Urology Partners
City
Riverview
State/Province
Florida
ZIP/Postal Code
33578
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
James E Alver, MD
Phone
813-685-0827
Email
alverje@gmail.com
Facility Name
Vero Urology Center
City
Vero Beach
State/Province
Florida
ZIP/Postal Code
32960
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
JOHN R ATWELL, MD
Phone
772-569-7606
Email
j.atwell@verourology.com
First Name & Middle Initial & Last Name & Degree
Andrew Prestini, PA-C
Phone
772-569-7606
Email
a.prestini@verourology.com
Facility Name
Urology Clinics of North Texas
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
JAMES S COCHRAN, ME
Phone
214-580-1391
Email
cochran@urologyclinics.com
First Name & Middle Initial & Last Name & Degree
STEPHANIE BERGER
Phone
214-580-1391
Email
sberger@urologyclinics.com

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
any Adverse Event (AE), Unanticipated AE will be shared with other researchers
IPD Sharing Time Frame
within 5 days of event and for duration of the study
IPD Sharing Access Criteria
all investigators will be emailed by the sponsor with the Adverse Event shared information
Citations:
PubMed Identifier
3292220
Citation
Fontanarosa PB, Roush WR. Acute urinary retention. Emerg Med Clin North Am. 1988 Aug;6(3):419-37.
Results Reference
result
PubMed Identifier
8858090
Citation
Samm BJ, Dmochowski RR. Urologic emergencies. Conditions affecting the kidney, ureter, bladder, prostate, and urethra. Postgrad Med. 1996 Oct;100(4):177-80, 183-4. doi: 10.3810/pgm.1996.10.100.
Results Reference
result
PubMed Identifier
9187688
Citation
Andersen JT, Nickel JC, Marshall VR, Schulman CC, Boyle P. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology. 1997 Jun;49(6):839-45. doi: 10.1016/s0090-4295(97)00185-4.
Results Reference
result
PubMed Identifier
9440858
Citation
de la Rosette JJ, Beerlage HP, Debruyne FM. Role of temporary stents in alternative treatment of benign prostatic hyperplasia. J Endourol. 1997 Dec;11(6):467-72. doi: 10.1089/end.1997.11.467.
Results Reference
result
Citation
Williams G. Stents in the lower urinary tract. European Urology Update Series 1992. Vol l (1), p 82-87.
Results Reference
result
PubMed Identifier
12073225
Citation
Devonec M, Dahlstrand C. Temporary urethral stenting after high-energy transurethral microwave thermotherapy of the prostate. World J Urol. 1998;16(2):120-3. doi: 10.1007/s003450050037.
Results Reference
result
PubMed Identifier
26383168
Citation
Feneley RC, Hopley IB, Wells PN. Urinary catheters: history, current status, adverse events and research agenda. J Med Eng Technol. 2015;39(8):459-70. doi: 10.3109/03091902.2015.1085600. Epub 2015 Sep 18. Erratum In: J Med Eng Technol. 2016;40(2):59.
Results Reference
result
Citation
Hammond, G. A Prospective Evaluation of the Catheter Science M3 "Mini Catheter" for Patients with Prostatic Obstruction. AUA Poster Presentation MP73-06, San Francisco, California, May, 2018
Results Reference
result
PubMed Identifier
30410822
Citation
Sabharwal S, Sabharwal S. Using Temporary Prostatic Stents to Eliminate Bacterial Colonization in Men with Chronic Indwelling Catheters: A Pilot Study. Cureus. 2018 Aug 16;10(8):e3152. doi: 10.7759/cureus.3152.
Results Reference
result
PubMed Identifier
17162043
Citation
Garcia MM, Gulati S, Liepmann D, Stackhouse GB, Greene K, Stoller ML. Traditional Foley drainage systems--do they drain the bladder? J Urol. 2007 Jan;177(1):203-7; discussion 207. doi: 10.1016/j.juro.2006.08.101.
Results Reference
result
PubMed Identifier
17296408
Citation
Shore ND, Dineen MK, Saslawsky MJ, Lumerman JH, Corica AP. A temporary intraurethral prostatic stent relieves prostatic obstruction following transurethral microwave thermotherapy. J Urol. 2007 Mar;177(3):1040-6. doi: 10.1016/j.juro.2006.10.059.
Results Reference
result

Learn more about this trial

Evaluation of the "Blue Halo Coil Catheter" for Patients With Prostatic Obstruction

We'll reach out to this number within 24 hrs